Squadron Capital Management LLC
An institutional investment manager in OAK BROOK, IL. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 14, 2026. SEC CIK 2050709.
- Reported value$322.2m
- Positions43
Holdings: 43 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Relmada Therapeutics IncRLMD | COM | 75955J402 | 50.9 | 15.8% | 7,350,000 | Reduced−1,124,571 | |
| C4 Therapeutics IncCCCC | COM STK | 12529R107 | 33.6 | 10.4% | 7,200,000 | Added+4,950,000 | |
| Cogent Biosciences IncCOGT | COM | 19240Q201 | 33.5 | 10.4% | 865,000 | Added+77,508 | |
| Kodiak Sciences IncKOD | COM | 50015M109 | 19.5 | 6.0% | 500,000 | Added+120,000 | |
| Relay Therapeutics IncRLAY | COM | 75943R102 | 18.1 | 5.6% | 970,000 | Added+297,500 | |
| Zentalis Pharmaceuticals IncZNTL | COM | 98943L107 | 17.9 | 5.6% | 3,700,000 | Added+69,000 | |
| Edgewise Therapeutics IncEWTX | COM | 28036F105 | 11.8 | 3.7% | 290,000 | Reduced−60,000 | |
| Maze Therapeutics IncMAZE | COM | 578784100 | 10.0 | 3.1% | 335,000 | Added+77,500 | |
| Inventiva SAIVA | ADS | 46124U107 | 9.2 | 2.9% | 2,435,000 | Added+1,900,000 | |
| Adlai Nortye LtdANL | SPONSORED ADS | 00704R109 | 8.8 | 2.7% | 764,876 | Reduced−500,355 | |
| Enliven Therapeutics IncELVN | COM | 29337E102 | 8.1 | 2.5% | 160,000 | New+160,000 | |
| Arrivent Biopharma IncAVBP | COM | 04272N102 | 6.4 | 2.0% | 183,000 | Call | Added+73,000 |
| Palisade Bio IncPALI | COM | 696389402 | 6.3 | 1.9% | 3,000,000 | Unchanged | |
| Bioage Labs IncBIOA | COM | 09077V100 | 6.1 | 1.9% | 250,000 | Call | New+250,000 |
| Inhibikase Therapeutics IncIKT | COM NEW | 45719W205 | 6.1 | 1.9% | 3,000,000 | Reduced−500,000 | |
| Adagene IncADAG | ADS | 005329107 | 5.3 | 1.6% | 1,250,000 | New+1,250,000 | |
| Forte Biosciences Inc | COM NEW | 34962G208 | 4.8 | 1.5% | 225,000 | New+225,000 | |
| Rezolute IncRZLT | COM NEW | 76200L309 | 4.7 | 1.5% | 900,000 | Call | New+900,000 |
| Inflarx NV | COM | N44821101 | 4.5 | 1.4% | 2,000,000 | New+2,000,000 | |
| Assembly Biosciences IncASMB | COM NEW | 045396207 | 4.4 | 1.4% | 160,000 | New+160,000 | |
| Compass Pathways plcCMPS | SPONSORED ADS | 20451W101 | 4.3 | 1.3% | 305,000 | Call | New+305,000 |
| Promis Neurosciences IncPMN | COM SHS | 74346M505 | 4.3 | 1.3% | 324,977 | Unchanged | |
| Contineum Therapeutics IncCTNM | CL A | 21217B100 | 4.3 | 1.3% | 260,000 | New+260,000 | |
| Compass Pathways plcCMPS | SPONSORED ADS | 20451W101 | 4.2 | 1.3% | 300,000 | New+300,000 | |
| Definium Therapeutics IncDFTX | COM SHS | 24477V105 | 4.0 | 1.2% | 85,000 | New+85,000 | |
| Sol-Gel Technologies Ltd | SHS NEW | M8694L137 | 3.9 | 1.2% | 52,000 | Added+21,000 | |
| Bioage Labs IncBIOA | COM | 09077V100 | 3.8 | 1.2% | 155,000 | New+155,000 | |
| Scynexis IncSCYX | COM | 811292309 | 3.1 | 1.0% | 756,884 | New+756,884 | |
| Proqr Thrapeutics N V | SHS EURO | N71542109 | 2.8 | 0.9% | 1,511,496 | New+1,511,496 | |
| Disc Medicine IncIRON | COM | 254604101 | 2.2 | 0.7% | 30,000 | Call | New+30,000 |
| Rezolute IncRZLT | COM NEW | 76200L309 | 2.1 | 0.7% | 403,410 | New+403,410 | |
| Lipocine Inc NewLPCN | COM NEW | 53630X203 | 2.1 | 0.6% | 810,000 | Added+360,000 | |
| Zentalis Pharmaceuticals IncZNTL | COM | 98943L107 | 2.1 | 0.6% | 426,000 | Call | Added+26,000 |
| C4 Therapeutics IncCCCC | COM STK | 12529R107 | 1.9 | 0.6% | 400,000 | Call | New+400,000 |
| Ultragenyx Pharmaceutical inRARE | COM | 90400D108 | 1.8 | 0.6% | 55,000 | Call | New+55,000 |
| CUE Biopharma IncCUE | COM | 22978P205 | 1.6 | 0.5% | 50,000 | New+50,000 | |
| Calcimedica Inc | COM NEW | 38942Q202 | 1.3 | 0.4% | 1,244,864 | New+1,244,864 | |
| Quince Therapeutics IncIRLA | COM | 22053A305 | 0.7 | 0.2% | 40,375 | New+40,375 | |
| Nuvectis Pharma IncNVCT | COM | 67080T108 | 0.7 | 0.2% | 38,700 | Call | New+38,700 |
| Pasithea Therapeutics CorpKTTA | COM NEW | 70261F202 | 0.5 | 0.2% | 1,000,000 | Reduced−1,100,000 | |
| Inmed Pharmaceuticals IncINM | COM NEW | 457637700 | 0.5 | 0.2% | 325,000 | New+325,000 | |
| Neumora Therapeutics Inc.NMRA | COM | 640979100 | 0.2 | <0.1% | 100,000 | New+100,000 | |
| Nextcure IncNXTC | COM NEW | 65343E207 | 0.1 | <0.1% | 64,464 | Reduced−200,536 |
Sold out: 18 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Abivax SAABVX | SPONSORED ADS | 00370M103 | 0.0 | 0.0% | 0 | Sold out−130,000 | |
| ALX Oncology Holdings IncALXO | COM | 00166B105 | 0.0 | 0.0% | 0 | Sold out−1,460,000 | |
| Context Therapeutics IncCNTX | COM | 21077P108 | 0.0 | 0.0% | 0 | Sold out−1,100,000 | |
| Eupraxia Pharmaceuticals IncEPRX | COM | 29842P105 | 0.0 | 0.0% | 0 | Sold out−680,000 | |
| GH Research plc | ORDINARY SHARES | G3855L106 | 0.0 | 0.0% | 0 | Sold out−325,000 | |
| Ideaya Biosciences IncIDYA | COM | 45166A102 | 0.0 | 0.0% | 0 | Put | Sold out−120,000 |
| Ideaya Biosciences IncIDYA | COM | 45166A102 | 0.0 | 0.0% | 0 | Call | Sold out−104,300 |
| Kalvista Pharmaceuticals Inc | COM | 483497103 | 0.0 | 0.0% | 0 | Sold out−985,100 | |
| Kalvista Pharmaceuticals Inc | COM | 483497103 | 0.0 | 0.0% | 0 | Call | Sold out−315,000 |
| Karyopharm Therapeutics IncKPTI | COM NEW | 48576U205 | 0.0 | 0.0% | 0 | Put | Sold out−750,000 |
| Nektar TherapeuticsNKTR | COM NEW | 640268306 | 0.0 | 0.0% | 0 | Sold out−125,000 | |
| Neuphoria Therapeutics IncNEUP | COM | 64136E102 | 0.0 | 0.0% | 0 | Sold out−76,728 | |
| Relay Therapeutics IncRLAY | COM | 75943R102 | 0.0 | 0.0% | 0 | Call | Sold out−150,000 |
| Scynexis Inc | COM NEW | 811292200 | 0.0 | 0.0% | 0 | Sold out−7,608,695 | |
| Spruce Biosciences IncSPRB | COM NEW | 85209E208 | 0.0 | 0.0% | 0 | Sold out−12,200 | |
| Therapeuticsmd IncTXMD | COM NEW | 88338N206 | 0.0 | 0.0% | 0 | Sold out−420,421 | |
| Traws Pharma IncTRAW | COM NEW | 68232V884 | 0.0 | 0.0% | 0 | Sold out−511,714 | |
| Werewolf Therapeutics IncHOWL | COM | 95075A107 | 0.0 | 0.0% | 0 | Sold out−563,535 |
Source: SEC EDGAR, Form 13F-HR, accession 0002050709-26-000027 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.